Liječnički vjesnik, Vol. 141 No. 7-8, 2019.
Pregledni rad
https://doi.org/10.26800/LV-141-7-8-30
Circulating microRNA expression in myelodysplastic syndrome
Inga Mandac Rogulj
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb; Zdravstveno veleučilište u Zagrebu, Zagreb
Vibor Milunović
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb
Mirjana Mariana Kardum Paro
; Klinički zavod za medicinsku biokemiju i laboratorijsku medicinu, Klinička bolnica Merkur, Zagreb
Delfa Radić Krišto
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb; Medicinski fakultet Sveučilišta u Osijeku, Osijek
Gordana Kaić
; Zavod za kliničku citologiju i citogenetiku, Klinička bolnica Merkur, Zagreb
Slobodanka Ostojić Kolonić
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb; Medicinski fakultet Sveučilišta u Zagrebu, Zagreb
Sažetak
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis and cytopenia in peripheral blood, where about a third of patients may develop acute
myeloid leukemia (AML). The diagnosis of MDS requires the analysis of peripheral blood and bone marrow. Depending on the percentage of blasts in the bone marrow, the number of cytopenias and cytogenetic abnormalities, determination of the prognostic indices is possible (IPSS - „International Prognostic Scoring System“, R-IPSS-„Revised International Prognostic Scoring System“, WPSS - „WHO Prognostic Scoring System“). Until today, numerous studies have been conducted on the molecular mechanisms and epigenetic pathways in myelodysplastic syndrome, and their prognostic and therapeutic importance, but there are few studies analyzing the importance of microRNAs (miRNAs) in MDS. In the last few years, there have been numerous results on the impact of aberrant miRNA expression in malignant disorders where the miRNA represent tumor suppressor genes or oncogenes. Several miRNAs have been recognized as diagnostic and prognostic parameters and possible therapeutic targets. In this paper, we present the overview of recent results on the role of miRNA in MDS.
Ključne riječi
MYELODYSPLASTIC SYNDROMES – diagnosis, genetics, pathology; MicroRNAs – blood, genetics; HEMATOPOIETIC STEM CELLS – pathology; GENE EXPRESSION PROFILING; LEUKEMIA, MYELOID, ACUTE – genetics; BIOMARKERS
Hrčak ID:
225770
URI
Datum izdavanja:
27.9.2019.
Posjeta: 1.915 *